Kibo Holds Performance Sharing Event for "Baby & Preliminary Unicorn" Companies

Over 100 Participants Including Company Representatives
IR Pitching Program and More Held

The Korea Technology Finance Corporation (Kibo) announced on the 27th that it held the "Baby & Preliminary Unicorn Performance Sharing and IR Event" at KINTEX in Goyang, Gyeonggi Province.

Busan Namgu Korea Technology Finance Corporation Headquarters. Kibo

This event, held as part of the first Venture Week, aimed to share the major achievements of Kibo's "Baby & Preliminary Unicorn Nurturing Program" and provide a platform for promising innovative companies to showcase their competitiveness, thereby facilitating the attraction of follow-up private investments.

The Baby Unicorn Nurturing Program is designed to discover early-stage startups with proven growth potential and help them grow into preliminary unicorns with a corporate value of over 100 billion won. The program provides up to 300 million won in market development funds and up to 5 billion won in special guarantees. Since 2020, Kibo has nurtured a total of 350 companies through this program. Among them, 18 companies have grown into preliminary unicorns, and 9 companies have been listed on KOSDAQ.

The Preliminary Unicorn Special Guarantee Program offers up to 20 billion won in special guarantees to innovative companies with a corporate value between 100 billion won and 1 trillion won, supporting their leap to unicorn status. Since 2019, Kibo has supported 141 companies through this program.

On this day, more than 100 participants, including companies in the nurturing programs, investors, and related organizations, attended the event. The event featured guidance on support programs, a performance presentation session, and an IR pitching program, all held in succession.

During the performance presentation session, three companies shared their growth stories and achievements: Colosseum Corporation, selected as a preliminary unicorn in 2025; Excell Therapeutics, selected as a preliminary unicorn in 2021 and later listed on KOSDAQ; and VS Pharmtech, selected as a baby unicorn in 2023 and subsequently attracting 4 billion won in investment.

In the subsequent IR event, First Biotherapeutics (preliminary unicorn for 2024), Dime Bio (baby unicorn for 2025), and Mr. Milk presented their technologies and business models through IR pitching. Active networking also took place between private investors and participating companies at the event.

Kim Joungho, Chairman of Kibo, stated, "The Global Unicorn Project has established itself as a representative scaling up program, driving numerous follow-up investments and global expansion," adding, "Kibo will continue to strengthen its support for baby and preliminary unicorn companies to help Korea become one of the world's top four venture powerhouses."

This content was produced with the assistance of AI translation services.